Patents by Inventor Zhen-yong Keck
Zhen-yong Keck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240016923Abstract: Disclosed are modified hepatitis C virus (HCV) E1E2 glycoproteins. Disclosed are Disclosed are modified HCV E1E2 glycoproteins comprising a HCV E1 polypeptide; a first scaffold element; a HCV E2 polypeptide; and a second scaffold element, wherein the HCV E1 polypeptide does not comprise a transmembrane domain, and wherein the HCV E2 polypeptide does not comprise a transmembrane domain.Type: ApplicationFiled: November 12, 2021Publication date: January 18, 2024Inventors: Brian G. Pierce, Thomas R. Fuerst, Eric A. Toth, Johnathan D. Guest, Steven K.H. Foung, Zhen-Yong Keck
-
Publication number: 20220054630Abstract: Disclosed are modified HCV E2 glycoproteins. Disclosed are modified HCV E2 glycoproteins comprising an antigenic domain D, wherein the modified HCV E2 glycoproteins comprise one or more amino acid alterations in the antigenic domain D, wherein at least one amino acid alteration is a proline substitution. In some aspects, the proline substitution occurs at position 445 based on the amino acid numbering of HCV strain H77. Disclosed are modified HCV E2 glycoproteins comprising an antigenic domain A, wherein the antigenic domain A comprises an N-glycan sequon substitution. In some aspects, the N-glycan sequon substitution results in an Asn-Xaa-Ser or Asn-Xaa-Thr substitution, wherein Xaa is any amino acid except proline. Also disclosed are methods of using the disclosed modified HCV E2 glycoproteins, such as methods of inducing an immune response in a subject, methods of treating a subject, and methods of increasing antigenicity of HCV E2 glycoprotein.Type: ApplicationFiled: August 18, 2021Publication date: February 24, 2022Inventors: Brian G. Pierce, Thomas R. Fuerst, Roy A. Mariuzza, Steven K.H. Foung, Zhen-Yong Keck
-
Patent number: 10611827Abstract: The disclosure provides non-human primate-derived binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.Type: GrantFiled: October 27, 2015Date of Patent: April 7, 2020Assignees: INTEGRATED BIOTHERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Mohammad Javad Aman, Frederick Wayne Holtsberg, Sven G. Enterlein, Katie A. Howell, Zhen-Yong Keck, Steven K. H. Foung
-
Publication number: 20170334973Abstract: The disclosure provides non-human primate-derived binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.Type: ApplicationFiled: October 27, 2015Publication date: November 23, 2017Inventors: Mohammad Javad AMAN, Frederick Wayne HOLTSBERG, Sven G. ENTERLEIN, Katie A. HOWELL, Zhen-Yong KECK, Steven K. H. FOUNG
-
Patent number: 9732121Abstract: Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of a neutralizing immune response.Type: GrantFiled: September 22, 2014Date of Patent: August 15, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Steven Foung, Zhen-Yong Keck, Thomas R. Fuerst
-
Publication number: 20150086580Abstract: Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of a neutralizing immune response.Type: ApplicationFiled: September 22, 2014Publication date: March 26, 2015Inventors: Steven Foung, Zhen-Yong Keck, Thomas R. Fuerst
-
Patent number: 8858947Abstract: The present invention provides identification and characterization of conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV). The present invention provides a panel of human monoclonal antibodies that recognize conformational epitopes of E2. The antibodies are derived from patients infected with HCV. The present invention provides methods for utilizing HCV antibodies as therapeutic, diagnostic, and/or prophylactic agents. The present invention provides mimotopes with conformational epitopes intact and methods of using mimotopes. The present invention provides methods of stratifying patients based on their response to HCV. The present invention provides pharmaceutical compositions for prevention and treatment of HCV comprising one or more HCV antibodies.Type: GrantFiled: October 5, 2008Date of Patent: October 14, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Steven Foung, Zhen-yong Keck
-
Publication number: 20130084301Abstract: Compositions and methods are provided relating to human anti-HCV E2 monoclonal antibodies. The antibodies of the invention bind to a conserved region of HCV E2 protein, and neutralize HCV influenza virus across multiple HCV genotypes. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the human anti-HCV monoclonal antibodies; and cell lines that produce these monoclonal antibodies.Type: ApplicationFiled: August 30, 2012Publication date: April 4, 2013Inventors: Steven Foung, Zhen-Yong Keck
-
Publication number: 20120039846Abstract: The present invention provides identification and characterization of conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV). The present invention provides a panel of human monoclonal antibodies that recognize conformational epitopes of E2. The antibodies are derived from patients infected with HCV. The present invention provides methods for utilizing HCV antibodies as therapeutic, diagnostic, and/or prophylactic agents. The present invention provides mimotopes with conformational epitopes intact and methods of using mimotopes. The present invention provides methods of stratifying patients based on their response to HCV. The present invention provides pharmaceutical compositions for prevention and treatment of HCV comprising one or more HCV antibodies.Type: ApplicationFiled: October 5, 2008Publication date: February 16, 2012Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Steven Foung, Zhen-yong Keck
-
Patent number: 8114586Abstract: Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.Type: GrantFiled: December 11, 2008Date of Patent: February 14, 2012Assignee: Board of Trustees of Leland Stanford Junior UniversityInventors: Steven K. H. Foung, Kenneth G. Hadlock, Zhen-yong Keck
-
Patent number: 7879326Abstract: A panel of IgG1 human monoclonal antibodies (HMAbs) identified by hemagglutination inhibition (HI) assay has been produced from peripheral B cells of an individual immunized with prototype H5N1 vaccine. Sequence analysis of antibody clones showed three clusters of different HMAbs as represented by HMAbs designated as BF1-1, BF1-19 and BF1-10. BF1-1 and BF1-10 have distinct CDR 1, 2 and 3 regions of both heavy and light chains. BF1-19 has the same heavy chain as BF1-1 but the light chain of BF1-10. Antibody binding affinity, KD, studies showed all three HMAbs ranging from at least about 10?8 to at least about 10?9. In vivo protection studies showed that these antibodies afforded significant protection against infection. These findings demonstrate that the antibodies of the invention are cross-neutralizing and therapeutic.Type: GrantFiled: June 16, 2008Date of Patent: February 1, 2011Assignees: The Board of Trustees of the Leland Stanford Junior University, St. Jude Children's Research HospitalInventors: Steven Foung, Zhen-Yong Keck, Richard Webby
-
Publication number: 20090202482Abstract: Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.Type: ApplicationFiled: December 11, 2008Publication date: August 13, 2009Inventors: Steven K. H. Foung, Kenneth G. Hadlock, Zhen-yong Keck
-
Publication number: 20090041679Abstract: A panel of IgG1 human monoclonal antibodies (HMAbs) identified by hemagglutination inhibition (HI) assay has been produced from peripheral B cells of an individual immunized with prototype H5N1 vaccine. Sequence analysis of antibody clones showed three clusters of different HMAbs as represented by HMAbs designated as BF1-1, BF1-19 and BF1-10. BF1-1 and BF1-10 have distinct CDR 1, 2 and 3 regions of both heavy and light chains. BF1-19 has the same heavy chain as BF1-1 but the light chain of BF1-10. Antibody binding affinity, KD, studies showed all three HMAbs ranging from at least about 10?8 to at least about 10?9. In vivo protection studies showed that these antibodies afforded significant protection against infection. These findings demonstrate that the antibodies of the invention are cross-neutralizing and therapeutic.Type: ApplicationFiled: June 16, 2008Publication date: February 12, 2009Inventors: Steven Foung, Zhen-Yong Keck, Richard Webby
-
Publication number: 20070032635Abstract: Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.Type: ApplicationFiled: August 15, 2006Publication date: February 8, 2007Inventors: Steven Foung, Kenneth Hadlock, Zhen-Yong Keck
-
Patent number: 7091324Abstract: Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.Type: GrantFiled: December 1, 2000Date of Patent: August 15, 2006Assignee: Board of Trustees of Leland Stanford Junior UniversityInventors: Steven K. H. Foung, Kenneth G. Hadlock, Zhen-yong Keck
-
Publication number: 20060104980Abstract: Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.Type: ApplicationFiled: December 1, 2000Publication date: May 18, 2006Inventors: Steven Foung, Kenneth Hadlock, Zhen-Yong Keck
-
Publication number: 20030180284Abstract: Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.Type: ApplicationFiled: July 2, 2002Publication date: September 25, 2003Applicant: Board of Trustees of Leland Stanford Junior UniversityInventors: Steven K. H. Foung, Zhen-Yong Keck